The overall objective of Duke's Clinical Oncology Research Career Development Program (PCACO), now called the Duke Paul Calabresi Award for Clinical Oncology (PCACO) remains the provision of career development support to junior faculty committed to clinical oncology therapeutic research careers at a time when new training methods are required to prepare future academic leaders for the major challenges of oncology research. In the last funding period, we have supported 17 Scholars, 12 male, and 5 female, with 10 Caucasian, 6 Asian, and 1 Hispanic, 14 from Duke and 3 recruited from other institutions including the National Cancer Institute, Johns Hopkins, and St. Jude. Most Scholars were Medical Oncologists (11), but we also supported 3 Surgeons and 1 Gynecologic Oncologist and two PhD scientists focused on pharamcogenetics and biomarkers. At this time, all Scholars are in active clinical and translational positions in academic medicine with 16 of 17 in academic medicine and one in industry. Eleven of 17 Scholars have obtained additional peer reviewed funding or awards including a Burroughs Wellcome Scholar, Doris Duke Clinical Scholar, V Foundation Scholar, Howard Hughes award, 3 K awards, and 3 American Cancer Society Scholars. Scholars have published over 70 peer reviewed manuscripts including reports in high impact journals such as the NEJM, JAMA, Lancet Oncology, Nature, Science, Nature Medicine, Nature Reviews, Journal of Clinical Oncology, Blood, Cancer, Clinical Cancer Research, Cancer Research, and the Journal of Immunology. The proposed PCACO proposes a career development program that allows integration of the enormous breadth of knowledge with the powerful statistical and computational approaches to extract important answers with an understand of the imperatives of managing complex infrastructure, as well as the vital ethical interactions with human experimental subjects

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Physician Scientist Award (Program) (PSA) (K12)
Project #
5K12CA100639-10
Application #
8535533
Study Section
Subcommittee G - Education (NCI)
Program Officer
Damico, Mark W
Project Start
2003-04-01
Project End
2014-07-31
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
10
Fiscal Year
2013
Total Cost
$839,728
Indirect Cost
$80,389
Name
Duke University
Department
Surgery
Type
Schools of Medicine
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Crosby, Erika J; Wei, Junping; Yang, Xiao Yi et al. (2018) Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors. Oncoimmunology 7:e1421891
Kim, Jihee; Grotegut, Chad A; Wisler, James W et al. (2018) ?-arrestin 1 regulates ?2-adrenergic receptor-mediated skeletal muscle hypertrophy and contractility. Skelet Muscle 8:39
Mackie, Duncan I; Al Mutairi, Fuad; Davis, Reema B et al. (2018) hCALCRL mutation causes autosomal recessive nonimmune hydrops fetalis with lymphatic dysplasia. J Exp Med 215:2339-2353
Snyder, Joshua C; Rochelle, Lauren K; Ray, Caroline et al. (2017) Inhibiting clathrin-mediated endocytosis of the leucine-rich G protein-coupled receptor-5 diminishes cell fitness. J Biol Chem 292:7208-7222
Zhu, Lu; Rossi, Mario; Cui, Yinghong et al. (2017) Hepatic ?-arrestin 2 is essential for maintaining euglycemia. J Clin Invest 127:2941-2945
Bhattacharyya, Jayanta; Ren, Xiu-Rong; Mook, Robert A et al. (2017) Niclosamide-conjugated polypeptide nanoparticles inhibit Wnt signaling and colon cancer growth. Nanoscale 9:12709-12717
Mook Jr, Robert A; Ren, Xiu-Rong; Wang, Jiangbo et al. (2017) Benzimidazole inhibitors from the Niclosamide chemotype inhibit Wnt/?-catenin signaling with selectivity over effects on ATP homeostasis. Bioorg Med Chem 25:1804-1816
Kanju, Patrick; Chen, Yong; Lee, Whasil et al. (2016) Small molecule dual-inhibitors of TRPV4 and TRPA1 for attenuation of inflammation and pain. Sci Rep 6:26894
Urs, Nikhil M; Gee, Steven M; Pack, Thomas F et al. (2016) Distinct cortical and striatal actions of a ?-arrestin-biased dopamine D2 receptor ligand reveal unique antipsychotic-like properties. Proc Natl Acad Sci U S A 113:E8178-E8186
Snyder, Joshua C; Pack, Thomas F; Rochelle, Lauren K et al. (2015) A rapid and affordable screening platform for membrane protein trafficking. BMC Biol 13:107

Showing the most recent 10 out of 38 publications